This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
The RO assay (receptor occupancy) measures how effectively the drug binds to the CCR5 receptor--in other words, it shows whether the drug is working or not.
I think they will get it largely because of unmet need. Hell, remdesivir got approved and they only lowered mortality 4% and their p-value wasn't statistically significant.
Ive seen no indication of the breakdown between severe and critical. If that exists, would like to see it.
Remdesivir being Gilead had a huge advantage though. Nobody takes Cytodyn seriously, I don't expect any breaks.
Humor me please and throw out a number. I won't hold it against you if you're wrong. Just curious what's your thinking because you seem to have insight that we don't have.
Thanks...just checking. Columbo here thought he'd cracked the code.
Nope, I said that vaccines will take away 90% of leronlimab's market. I stand by that.
It is not an assumption. It is a memory. But I've already said that I might be mistaken.
With the rate vaccinations are going and the number of people refusing to take them, I think that number will be greatly diminished
Vaccines are potentially going to take away a percentage of the market but the vaccines are not mandatory and people are very hesitant to take them. Not sure how you figure such a high number when there will be a very high number of people who refuse the vaccine.
Even without vaccines, herd immunity eventually comes. Look at the Spanish Flu of 1918, it peaked in its second year and then diminished rapidly. Vaccines will just speed up the process.
Nope, I said that vaccines will take away 90% of leronlimab's market. I stand by that.
It is not an assumption. It is a memory. But I've already said that I might be mistaken.
Look at the current flu, there is no herd immunity there. We get an annual vaccine to hopefully diminish the chances of catching it for that year but even then the strain mutates and the vaccine can be ineffective. Hopefully the vaccine gives a person a few years of immunity to help lower the numbers but it's already starting to mutate into different strains, therapeutically drugs are going to be very important for a long time. This is all based off talking to the PHS that works in my office, he was one of the lead PHS doctors running the covid information for the CG.Don Hutson said:
I would think the critical would have more. My belief is that someone is more likely to accept an experimental drug when on death's door rather then just needing some oxygen.
I thought it was 66% severe and 33% critical. I thought I remembered those numbers from the interim analysis. But I might also have gotten that ratio from Otto Yang's eINDS patients.
Have you loaded up on CYDY shares yet?Don Hutson said:
I have to agree with this. They also had to have a good idea of what kind of patients they needed to recruit at the 50% mark. They likely got that part right.
I think the Shorts may have gotten burned on their last attempt. They got the stock down to the low 4's, but I think a big player came in right after them and gobbled everything up to bring the stock price close to 5.
